Medindia1d
Molecular Infectious Disease Testing Market to Hit USD 17.78 Billion by 2029 with 13.7% CAGR | MarketsandMarkets™.
The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching US$9.37 billion in 2024 and an impressive US$17.78 ...
Molecular Infectious Disease Testing Market to Hit USD 17.78 Billion by 2029 with 13.7% CAGR | MarketsandMarkets.
The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, ...
Roche upgraded to Buy from Neutral at UBS
UBS upgraded Roche (RHHBY) to Buy from Neutral with a price target of CHF 338, up from CHF 300. The company offers sustainable growth with ...
UBS lifts Roche stock rating to Buy, raises target to CHF338
UBS analyst Matthew Weston upgraded Roche Holding (OTC:RHHBY) stock from Neutral to Buy, adjusting the price target to CHF 338.00, up from the previous CHF 300.00. The upgrade comes as the stock ...
FierceBiotech2d
VC Longwood Fund unveils neuro biotech with $93M, assets licensed from Roche
Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience ...
Roche initiated with an Equal Weight at Morgan Stanley
Morgan Stanley initiated coverage of Roche (RHHBY) with an Equal Weight rating and CHF 305 price target The firm sees the end of Roche’s ...